Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation

Stroke

Volumn 45, Issue 2, 2014, Pages 426-431

  Aakre, Christopher A ^a   McLeod, Christopher J ^a   Cha, Stephen S ^a   Tsang, Teresa S M ^b   Lip, Gregory Y H ^c   Gersh, Bernard J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFORMATION PROCESSING; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PREDICTION; PREDICTIVE VALUE; PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VALIDATION STUDY;

ATRIAL FIBRILLATION; STROKE;

AGED; ALGORITHMS; ATRIAL FIBRILLATION; BLOOD PRESSURE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HEART RATE; HUMANS; HYPERTENSION; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; STROKE; THROMBOEMBOLISM;

EID: 84893728913     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002585     Document Type: Article

References (31)

1. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
3. Hughes M, Lip GY; Guideline Development Group for the NICE National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100:599-607.
4. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124: 111-114.
5. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al.; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997-1011.
6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
7. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-2292.
8. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with newonset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056.
9. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810-815.
10. Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011;22:25-30.
11. Ruiz Ortiz M, Romo E, Mesa D, Delgado M, Anguita M, Castillo JC, et al. Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. Cardiology. 2010;115:200-204.
12. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-2738.
13. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. Circulation. 2006;114:e257-354.
14. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
15. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.
16. National Collaborating Centre for Chronic Conditions (UK). Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians (UK); 2006.
17. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA. 1998;279:1273-1277.
18. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e531S-e575S.
19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
20. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972:187-220.
21. Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140:918-924.
22. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101:367-372.
23. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9:39-48.
24. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500-1510.
25. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14-21.
26. Camm AJ, Corbucci G, Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol. 2012;110:270-276.
27. Taillandier S, Olesen JB, Clémenty N, Lagrenade I, Babuty D, Lip GY, et al. Prognosis in patients with atrial fibrillation and CHA2DS2- VASc Score = 0 in a community-based cohort study. J Cardiovasc Electrophysiol. 2012;23:708-713.
28. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172-1179.
29. Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes. 2012;5:335-342.
30. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106:739-749.
31. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489-496.